Loading clinical trials...
Loading clinical trials...
Single-center, Before-and-after Study Evaluating the Impact of BacT/Alert® VIRTUO®, BioFire® Blood Culture Identification 2-BCID2 and REVEAL® (bioMérieux) on the Optimization of Antibiotic Therapy for Gram-negative Bacteremia in the ICU Patient
Conditions
Interventions
Innovative diagnostic technologies
Reference diagnostic technique
Locations
1
France
CHU de Nîmes
Nîmes, France
Start Date
March 8, 2023
Primary Completion Date
May 6, 2024
Completion Date
June 16, 2024
Last Updated
January 13, 2026
NCT06650501
NCT07299539
NCT06135350
NCT06336824
NCT06874920
NCT06970899
Lead Sponsor
Centre Hospitalier Universitaire de Nīmes
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions